Information on EC 5.3.3.5 - cholestenol DELTA-isomerase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY
5.3.3.5
-
RECOMMENDED NAME
GeneOntology No.
cholestenol DELTA-isomerase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
5alpha-Cholest-7-en-3beta-ol = 5alpha-cholest-8-en-3beta-ol
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
intramolecular oxidoreduction
-
-
-
-
isomerization
-
-
-
-
PATHWAY
KEGG Link
MetaCyc Link
Biosynthesis of secondary metabolites
-
cholesterol biosynthesis I
-
cholesterol biosynthesis II (via 24,25-dihydrolanosterol)
-
cholesterol biosynthesis III (via desmosterol)
-
Metabolic pathways
-
plant sterol biosynthesis
-
Steroid biosynthesis
-
SYSTEMATIC NAME
IUBMB Comments
DELTA7-Cholestenol DELTA7-DELTA8-isomerase
-
SYNONYMS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
3beta-hydroxysteroid DELTA8-DELTA7 isomerase
-
-
C-8,7 sterol isomerase
-
-
Cholestenol delta-isomerase
-
-
-
-
D8-D7 sterol isomerase
-
-
-
-
D8D7I
-
-
DELTA8-Cholestenol-DELTA7-cholestenol isomerase
-
-
-
-
Delta8-delta7 sterol isomerase
-
-
-
-
Delta8-delta7 sterol isomerase
-
-
DELTA8-SI
-
-
EBP
Q15125
-
EBP
-
-
Emopamil binding protein
-
-
-
-
Emopamil binding protein
-
-
Emopamil binding protein
Q15125
-
Isomerase, cholestenol DELTA-
-
-
-
-
sterol 8,7-isomerase
-
-
sterol DELTA8 isomerase
-
-
CAS REGISTRY NUMBER
COMMENTARY
37318-47-1
-
GENERAL INFORMATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
physiological function
-
the enzyme is involved in the ergosterol production. Pharmacological relationship between sigma ligand-binding and C-8,7 sterol isomerase activity, the C-8,7 sterol isomerase that contains a sigma ligand binding site
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
26,27-dehydrozymosterol
5beta-cholest-7-en-3beta-ol
show the reaction diagram
Q15125
-
-
?
26,27-dinorcholesta-8,24-dienol
26,27-dinorcholesta-7,24-dienol
show the reaction diagram
Q15125
-
-
?
26-homo-cholesta-8(9),23(24) E26(26')-trienol
26-homo-cholesta-7(8),23(24)E26(26')trienol
show the reaction diagram
Q15125
-
-
?
4alpha-methyl-5alpha-ergosta-8,24-dien-3beta-ol
24-methylenelophenol
show the reaction diagram
-
-
i.e. 4alpha-methyl-5alpha-ergosta-7,24-dien-3beta-ol
-
-
4alpha-methyl-ergosta-8,24-dien-3beta-ol
?
show the reaction diagram
-
-
-
-
?
4alpha-methyl-fecosterol
4alpha-methyl-ergosta-7,24-dien-3beta-ol
show the reaction diagram
-
-
-
-
?
5alpha-Cholest-7-en-3beta-ol
5alpha-Cholest-8-en-3beta-ol
show the reaction diagram
-
-
-
-
5alpha-Cholest-7-en-3beta-ol
5alpha-Cholest-8-en-3beta-ol
show the reaction diagram
-
r
-
-
5alpha-Cholest-7-en-3beta-ol
5alpha-Cholest-8-en-3beta-ol
show the reaction diagram
-
r
-
-
5alpha-cholest-7-en-3beta-ol
?
show the reaction diagram
Q9JJ46
enzyme of the cholesterol biosynthetic pathway, mutations are associated with Conradi-Huenermann syndrome. The enzyme may be involved in liver function, since the mRNA is only detected in hepatocytes not in connective tissue or blood vessels. The expression of the SI gene is regulated transcriptionally in vitro and in vivo by widely known regulatory agents ranging from tamoxifen, an oestrogen receptor antagonist and SI-specific inhibitor, to cholesterol-lowering drugs
-
?
5alpha-cholesta-8,24-dien-3beta-ol
5alpha-cholesta-7,24-dien-3beta-ol
show the reaction diagram
Q15125
-
-
-
-
5alpha-cholesta-8,24-dien-3beta-ol
5alpha-cholesta-7,24-dien-3beta-ol
show the reaction diagram
-
-
-
-
?
cholest-8-enol
cholest-7-enol
show the reaction diagram
Q15125
-
-
?
cholesta-8,24-dien-3beta-ol
?
show the reaction diagram
-
-
-
-
?
DELTA8-sitostenol
stigmast-7-en-3beta-ol
show the reaction diagram
-
-
-
-
?
dihydrozymosterol
lathosterol
show the reaction diagram
-
-
-
-
?
stigmasta-8-en-3beta-ol
?
show the reaction diagram
-
-
-
-
?
zymosterol
cholesta-7,24-dienol
show the reaction diagram
-
-
-
-
?
zymosterol
cholesta-7,24-dienol
show the reaction diagram
Q15125
preferred substrate for DELTA7-sterol production, the reaction equilibrium for double-bond isomerization favours the forward direction, DELTA8 to DELTA7
-
r
fecosterol
24-methylene-5alpha-cholest-7-en-3beta-ol
show the reaction diagram
Q15125
-
-
?
additional information
?
-
Q15125
3-desoxyzymosterol is not an active substrate
-
?
additional information
?
-
-
4,4-dimethyl-cholesta-8,24-dien-3beta-ol, 4,4-dimethyl-ergosta-8,24-dien-3beta-ol, 4alpha,14aloha-dimethyl-ergosta-8,24-dien-3beta-ol, and cholest-8(14)-en-3beta-ol are no substrates
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
5alpha-cholest-7-en-3beta-ol
?
show the reaction diagram
Q9JJ46
enzyme of the cholesterol biosynthetic pathway, mutations are associated with Conradi-Huenermann syndrome. The enzyme may be involved in liver function, since the mRNA is only detected in hepatocytes not in connective tissue or blood vessels. The expression of the SI gene is regulated transcriptionally in vitro and in vivo by widely known regulatory agents ranging from tamoxifen, an oestrogen receptor antagonist and SI-specific inhibitor, to cholesterol-lowering drugs
-
?
INHIBITORS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
(+)-emopamil
Q60490
-
(+)-emopamil
-
;
(+)-emopamil
P70245
-
(+)-pentazocine
-
-
(+)-pentazocine
-
i.e. (+)-[2S-(2R,6R,11R)]-1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocine-8-ol
(+)-verapamil
Q60490
-
(+)-verapamil
-
;
(+)-verapamil
P70245
-
(+/-)-ifenprodil
-
-
(-)-emopamil
Q60490
IC50: 28 nM for the liver enzyme, IC50: 34 nM for the brain enzyme
(-)-emopamil
-
;
(-)-emopamil
P70245
-
(-)-verapamil
Q60490
-
(-)-verapamil
-
;
(-)-verapamil
P70245
-
(R,S)-1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)-n-propyl]piperazine
-
-
-
1,3-di-2-tolylguanidine
-
-
1-cyclohexyl-4-[cis-4-(2,6-difluorophenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[cis-4-(2,6-dimethoxyphenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[cis-4-(2-methoxyphenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[cis-4-(2-methylphenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[cis-4-(4-methoxyphenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[trans-4-(2,6-difluorophenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[trans-4-(2,6-dimethoxyphenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[trans-4-(2-methoxyphenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[trans-4-(2-methylphenyl)cyclohexyl]piperazine
-
-
1-cyclohexyl-4-[trans-4-(4-methoxyphenyl)cyclohexyl]piperazine
-
-
1-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]-4-pyridin-2-ylpiperazine
-
-
1-[4-(3-methoxyphenyl)cyclohex-3-en-1-yl]-4-phenylpiperazine
-
-
1-[4-(3-methoxyphenyl)cyclohex-3-en-1-yl]-4-pyridin-2-ylpiperazine
-
-
1-[4-(3-methoxyphenyl)cyclohexyl]-4-phenylpiperazine
-
-
1-[cis-4-(2-chlorophenyl)cyclohexyl]-4-cyclohexylpiperazine
-
-
1-[cis-4-(2-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
1-[cis-4-(3-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
1-[cis-4-(4-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
1-[trans-4-(2-chlorophenyl)cyclohexyl]-4-cyclohexylpiperazine
-
-
1-[trans-4-(2-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
1-[trans-4-(3-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
1-[trans-4-(4-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
2-[4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy]-N,N-dimethylethanamine
-
noncompetitive, IC50: 0.00025 mM
25-Azacholesterol
-
-
3-[4-(4-naphthalen-1-ylpiperazin-1-yl)cyclohexyl]phenyl hydroperoxide
-
-
3beta-[2-(diethylamino)ethoxy]androst-5-en-17-one
Q9JJ46
IC50: 0.0042 mM
4-[1-(2,6-dimethylphenyl)-3-cyclohexen-4-yl]-1-(2-pyridinyl)piperazine
-
-
amiodarone
Q60490
-
amiodarone
-
;
amiodarone
P70245
-
AY9944
-
-
cholesterol
-
-
cis-1-cyclohexyl-4-(4-phenylcyclohexyl)piperazine
-
-
-
cis-1-cyclohexyl-4-[(3-methoxyphenyl)cyclohexyl]piperazine
-
-
-
cis-4-(4-phenylcyclohexyl)-1-(2-pyridinyl)piperazine
-
-
cis-4-[4-(2,6-difluorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
cis-4-[4-(2,6-dimethoxyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
cis-4-[4-(2,6-dimethylyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
cis-4-[4-(2-chlorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
cis-4-[4-(2-methylphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
CuCl2
Q60490
IC50: 0.01 mM, ifenprodil-labeled enzyme
CuCl2
-
IC50: 0.0023 mM, ifenprodil-labeled enzyme
CuCl2
P70245
IC50: 0.0011 mM, ifenprodil-labled enzyme
CuCl2
-
IC50: 0.57 mM, ifenprodil-labeled enzyme
ditolylguanidine
Q60490
IC50: 122 nM for the liver enzyme, IC50: 36 nM for the brain enzyme
ditolylguanidine
-
;
ditolylguanidine
P70245
-
enclomiphene
-
;
fenpropimorph
-
;
fenpropimorph
-
-
haloperidol
Q60490
IC50: 6.8 nM for the liver enzyme, 23 nM for the brain enzyme
haloperidol
-
;
haloperidol
P70245
-
ifenprodil
-
-
ifenprodil
Q60490
IC50: 2.4 nM for the liver enzyme, 1.7 nM for the brain enzyme
ifenprodil
-
;
Ketoconazole
-
-
L690404
Q60490
-
L690404
P70245
-
N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine
-
-
N-(2-phenylethyl)piperidine
-
-
nafoxidine
-
;
naftifine
-
;
opipramol
Q60490
-
opipramol
-
;
opipramol
P70245
-
tamoxifen
-
-
tamoxifen
-
;
tamoxifen
-
-
trans-1-cyclohexyl-4-(4-phenylcyclohexyl)piperazine
-
-
-
trans-1-cyclohexyl-4-[(3-methoxyphenyl)cyclohexyl]piperazine
-
-
-
trans-2-[4-(1,2-diphenylbuten-1-yl)phenoxy]-N,N-dimethylethylamine
Q9JJ46
IC50: 0.0112 mM
trans-4-(4-phenylcyclohexyl)-1-(2-pyridinyl)piperazine
-
-
trans-4-[4-(2,6-difluorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
trans-4-[4-(2,6-dimethoxyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
trans-4-[4-(2-chlorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
trans-4-[4-(2-methylphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
tridemorph
-
-
tridemorph
-
;
tridemorph
-
-
Trifluoperazine
Q60490
IC50: 11 nM for the liver enzyme, IC50: 13 nM for the brain enzyme
Trifluoperazine
-
;
Trifluoperazine
P70245
-
Trifluoperazine
-
-
trifluoroperazine
-
-
trifluperidol
-
;
Triparanol
-
;
verapamil
Q60490
-
verapamil
-
-
verapamil
P70245
-
ZnCl2
Q60490
IC50: 0.001 mM, ifenprodil-labeled enzyme
ZnCl2
-
IC50: 0.0006 mM, ifenprodil-labeled enzyme
ZnCl2
P70245
IC50: 0.001 mM, ifenprodil-labeled enzyme
ZnCl2
-
IC50: 0.0044 mM, ifenprodil-labeled enzyme
zuclomiphene
-
;
additional information
-
not inhibited by N-benzamido-decalin, tamoxifen, N-benzyl-8-azadecalin, and AY9944
-
additional information
-
not inhibited by N-benzamido-decalin
-
KM VALUE [mM]
KM VALUE [mM] Maximum
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.522
-
4alpha-methyl-ergosta-8,24-dien-3beta-ol
-
-
0.512
-
cholesta-8,24-dien-3beta-ol
-
-
0.116
-
stigmasta-8-en-3beta-ol
-
-
0.05
-
Zymosterol
-
-
TURNOVER NUMBER [1/s]
TURNOVER NUMBER MAXIMUM[1/s]
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.423
-
Zymosterol
-
-
Ki VALUE [mM]
Ki VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
2.3e-06
-
(+)-emopamil
Q60490
-
1.9e-05
-
(+)-emopamil
-
-
7.7e-05
-
(+)-emopamil
P70245
-
0.01
-
(+)-pentazocine
-
Ki above 0.01 mM
0.00089
-
(+)-verapamil
Q60490
-
0.0029
-
(+)-verapamil
-
-
0.00363
-
(+)-verapamil
P70245
-
0.00407
-
(+)-verapamil
-
-
1.47e-05
-
(+/-)-ifenprodil
-
pH and temperature not specified in the publication
1.64e-05
-
(+/-)-ifenprodil
-
-
1e-05
-
(-)-emopamil
Q60490
-
2e-05
-
(-)-emopamil
-
-
2.3e-05
-
(-)-emopamil
P70245
-
0.00152
-
(-)-verapamil
P70245
-
0.00269
-
(-)-verapamil
-
-
0.0029
-
(-)-verapamil
Q60490
-
0.00766
-
1,3-di-2-tolylguanidine
-
-
1.6e-05
-
1-cyclohexyl-4-[cis-4-(2,6-difluorophenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
7.6e-06
-
1-cyclohexyl-4-[cis-4-(2,6-dimethoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
4.1e-06
-
1-cyclohexyl-4-[cis-4-(2-methoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
9e-06
-
1-cyclohexyl-4-[cis-4-(2-methylphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
6.51e-06
-
1-cyclohexyl-4-[cis-4-(4-methoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
1.8e-05
-
1-cyclohexyl-4-[trans-4-(2,6-difluorophenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
1.1e-05
-
1-cyclohexyl-4-[trans-4-(2,6-dimethoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
1.07e-05
-
1-cyclohexyl-4-[trans-4-(2-methoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
9.73e-06
-
1-cyclohexyl-4-[trans-4-(2-methylphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
1.36e-05
-
1-cyclohexyl-4-[trans-4-(4-methoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
3.21e-05
-
1-[(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]-4-pyridin-2-ylpiperazine
-
-
0.00046
-
1-[4-(3-methoxyphenyl)cyclohex-3-en-1-yl]-4-phenylpiperazine
-
-
0.00264
-
1-[4-(3-methoxyphenyl)cyclohex-3-en-1-yl]-4-pyridin-2-ylpiperazine
-
-
0.00171
-
1-[4-(3-methoxyphenyl)cyclohexyl]-4-phenylpiperazine
-
-
1.69e-05
-
1-[cis-4-(2-chlorophenyl)cyclohexyl]-4-cyclohexylpiperazine
-
pH and temperature not specified in the publication
8.15e-06
-
1-[cis-4-(2-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
4.54e-05
-
1-[cis-4-(3-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
3.28e-05
-
1-[cis-4-(4-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
2.06e-05
-
1-[trans-4-(2-chlorophenyl)cyclohexyl]-4-cyclohexylpiperazine
-
pH and temperature not specified in the publication
1.35e-05
-
1-[trans-4-(2-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
1.62e-05
-
1-[trans-4-(3-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
7.16e-05
-
1-[trans-4-(4-methoxyphenyl)cyclohexyl]-4-pyridin-2-ylpiperazine
-
-
0.021
-
25-Azacholesterol
-
-
1.67e-05
-
3-[4-(4-naphthalen-1-ylpiperazin-1-yl)cyclohexyl]phenyl hydroperoxide
-
-
4.67e-05
-
4-[1-(2,6-dimethylphenyl)-3-cyclohexen-4-yl]-1-(2-pyridinyl)piperazine
-
-
1.6e-05
-
amiodarone
Q60490
-
3.5e-05
-
amiodarone
-
-
6e-05
-
amiodarone
P70245
-
1.2e-05
-
AY9944
-
-
0.01648
-
BM15766
-
-
0.034
-
BM15766
-
-
0.62
-
cholesterol
-
37°C
1.23e-05
-
cis-1-cyclohexyl-4-(4-phenylcyclohexyl)piperazine
-
pH and temperature not specified in the publication
-
1.26e-05
-
cis-1-cyclohexyl-4-[(3-methoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
-
4.92e-05
-
cis-4-(4-phenylcyclohexyl)-1-(2-pyridinyl)piperazine
-
-
0.00014
-
cis-4-[4-(2,6-difluorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
4.95e-06
-
cis-4-[4-(2,6-dimethoxyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
4.95e-06
-
cis-4-[4-(2,6-dimethoxyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
pH and temperature not specified in the publication
3.31e-05
-
cis-4-[4-(2,6-dimethylyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
8.51e-05
-
cis-4-[4-(2-chlorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
5e-06
-
cis-4-[4-(2-methylphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
0.0043
-
ditolylguanidine
P70245
-
0.0106
-
ditolylguanidine
Q60490
-
0.0144
-
ditolylguanidine
-
-
0.002
-
emopamil
-
-
6.9e-07
-
enclomiphene
-
-
4.4e-05
-
fenpropimorph
-
-
3.5e-05
-
haloperidol
-
-
0.00025
-
haloperidol
Q60490
-
0.000435
-
haloperidol
P70245
-
6e-06
-
ifenprodil
-
-
0.156
-
Ketoconazole
-
-
1e-06
-
L690404
Q60490
-
2.3e-06
-
L690404
-
-
5e-07
-
MDL28815
-
-
6.7e-07
-
MDL5332
-
-
5.4e-05
-
MDL5332
-
-
1.46e-05
-
N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine
-
-
0.000595
-
N-(2-phenylethyl)piperidine
-
-
9e-07
-
nafoxidine
-
-
0.000232
-
nafoxidine
-
-
0.00031
-
naftifine
-
-
0.0015
-
naftifine
-
-
3.8e-06
-
opipramol
-
-
8.5e-06
-
opipramol
Q60490
-
4.7e-05
-
opipramol
P70245
-
2.8e-06
-
tamoxifen
-
-
0.00021
-
tamoxifen
-
-
0.001
-
tamoxifen
-
-
1.42e-05
-
trans-1-cyclohexyl-4-(4-phenylcyclohexyl)piperazine
-
pH and temperature not specified in the publication
-
4e-07
-
trans-1-cyclohexyl-4-[(3-methoxyphenyl)cyclohexyl]piperazine
-
pH and temperature not specified in the publication
-
1.68e-05
-
trans-4-(4-phenylcyclohexyl)-1-(2-pyridinyl)piperazine
-
-
0.000106
-
trans-4-[4-(2,6-difluorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
7e-06
-
trans-4-[4-(2,6-dimethoxyphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
7.21e-06
-
trans-4-[4-(2-chlorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
9.04e-06
-
trans-4-[4-(2-methylphenyl)cyclohexyl]-1-(2-pyridinyl)piperazine
-
-
1.3e-06
-
tridemorph
-
-
0.001
-
tridemorph
-
-
3.6e-06
-
Trifluoperazine
-
-
7.7e-06
-
Trifluoperazine
P70245
-
3.9e-06
-
trifluoroperazine
Q60490
-
0.000354
-
trifluperidol
-
-
1.4e-05
-
Triparanol
-
-
1.9e-06
-
U18666A
-
-
0.0019
-
U18666A
-
-
3e-06
-
zuclomiphene
-
-
IC50 VALUE [mM]
IC50 VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
2.8e-05
-
(-)-emopamil
Q60490
IC50: 28 nM for the liver enzyme
3.4e-05
-
(-)-emopamil
Q60490
IC50: 34 nM for the brain enzyme
0.00025
-
2-[4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy]-N,N-dimethylethanamine
-
noncompetitive, IC50: 0.00025 mM
0.0042
-
3beta-[2-(diethylamino)ethoxy]androst-5-en-17-one
Q9JJ46
IC50: 0.0042 mM
0.0001
-
AY9944
-
-
0.0011
-
CuCl2
P70245
IC50: 0.0011 mM, ifenprodil-labled enzyme
0.0023
-
CuCl2
-
IC50: 0.0023 mM, ifenprodil-labeled enzyme
0.01
-
CuCl2
Q60490
IC50: 0.01 mM, ifenprodil-labeled enzyme
0.57
-
CuCl2
-
IC50: 0.57 mM, ifenprodil-labeled enzyme
3.6e-05
-
ditolylguanidine
Q60490
IC50: 36 nM for the brain enzyme
0.000122
-
ditolylguanidine
Q60490
IC50: 122 nM for the liver enzyme
3e-05
-
fenpropimorph
-
-
0.00021
-
fenpropimorph
-
-
6.8e-06
-
haloperidol
Q60490
IC50: 6.8 nM for the liver enzyme
2.3e-05
-
haloperidol
Q60490
23 nM for the brain enzyme
1.7e-06
-
ifenprodil
Q60490
1.7 nM for the brain enzyme
2.4e-06
-
ifenprodil
Q60490
IC50: 2.4 nM for the liver enzyme
0.0001
-
SR31747
-
-
0.0085
-
tamoxifen
-
-
0.0112
-
trans-2-[4-(1,2-diphenylbuten-1-yl)phenoxy]-N,N-dimethylethylamine
Q9JJ46
IC50: 0.0112 mM
0.00085
-
tridemorph
-
-
0.001
-
tridemorph
-
-
1.1e-05
-
Trifluoperazine
Q60490
IC50: 11 nM for the liver enzyme
1.3e-05
-
Trifluoperazine
Q60490
IC50: 13 nM for the brain enzyme
0.001
-
Trifluoperazine
-
-
0.5
-
Trifluoperazine
-
IC50 above 0.5 mM
0.0006
-
ZnCl2
-
IC50: 0.0006 mM, ifenprodil-labeled enzyme
0.001
-
ZnCl2
Q60490
IC50: 0.001 mM, ifenprodil-labeled enzyme
0.001
-
ZnCl2
P70245
IC50: 0.001 mM, ifenprodil-labeled enzyme
0.0044
-
ZnCl2
-
IC50: 0.0044 mM, ifenprodil-labeled enzyme
SPECIFIC ACTIVITY [µmol/min/mg]
SPECIFIC ACTIVITY MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
0.243
-
-
-
pH OPTIMUM
pH MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
7.5
-
-
-
TEMPERATURE OPTIMUM
TEMPERATURE OPTIMUM MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
35
45
-
-
pI VALUE
pI VALUE MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
7.7
-
-
-
SOURCE TISSUE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
SOURCE
LOCALIZATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
putative transmembrane spanning domains
Manually annotated by BRENDA team
MOLECULAR WEIGHT
MOLECULAR WEIGHT MAXIMUM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
27000
-
-
-
107000
-
-
gel filtration
SUBUNITS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
?
Q9JJ46
x * 26737, calculation from nucleotide sequence
?
-
x * 21000, about, sequence calculation; x * 26737, calculation from nucleotide sequence
tetramer
-
4 * 26700, MALDI-TOF mass spectrometry; 4 * 27000, SDS-PAGE
STORAGE STABILITY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
-20°C, crude enzyme preparation, stable for 2 months
-
Purification/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
recombinant enzyme
-
Cloned/COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
the full-length cDNA that complements the erg2 mutation contains an open reading frame encoding a 21000 Da protein that shares 68% similarity and 35% amino acid identity to the recently isolated mouse C8,7 sterol isomerase
-
coexpression of D8D7I and DHCR7 in COS-7 cells produces a high affinity binding site for tritiated tamoxifen that displays the pharmacological profile of the antiestrogen binding site found in tumor cells
-
overexpression in erg2 Saccharomyces cerevisiae and in Escherichia coli
-
expression in Saccharomyces cerevisiae
Q9JJ46
expressed in the Saccharomyces cerevisiae mutant erg2
-
ENGINEERING
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
C121A
-
mutant enzyme with 95% of the in vivo activity of the wild-type enzyme
C128A
-
mutant enzyme with 81% of the in vivo activity of the wild-type enzyme
C68A
-
mutant enzyme with 94% of the in vivo activity of the wild-type enzyme
C73A
-
mutant enzyme with 83% of the in vivo activity of the wild-type enzyme
E123A
-
mutant enzyme with 10% of the in vivo activity of the wild-type enzyme
E123D
-
mutant enzyme does not bind the inhibitor ifenprodil
E81A
-
mutant enzyme with 5% of the in vivo activity of the wild-type enzyme
E81D
-
mutant enzyme still binds the inhibitor ifenprodil
F186A
-
mutant enzyme with 56% of the in vivo activity of the wild-type enzyme
F188A
-
mutant enzyme with 94% of the in vivo activity of the wild-type enzyme
F190A
-
mutant enzyme with 21% of the in vivo activity of the wild-type enzyme
F192A
-
mutant enzyme with 92% of the in vivo activity of the wild-type enzyme
F37A
-
mutant enzyme with 74% of the in vivo activity of the wild-type enzyme
F70A
-
mutant enzyme with 95% of the in vivo activity of the wild-type enzyme
F75A
-
mutant enzyme with 88% of the in vivo activity of the wild-type enzyme
F84A
-
mutant enzyme with 72% of the in vivo activity of the wild-type enzyme
G131A
-
mutant enzyme with 69% of the in vivo activity of the wild-type enzyme
G41A
-
mutant enzyme with 94% of the in vivo activity of the wild-type enzyme
G82A/F84V
-
mutant enzyme with 56% of the in vivo activity of the wild-type enzyme
H31A
-
mutant enzyme with 69% of the in vivo activity of the wild-type enzyme
H77A
-
mutant enzyme with 9% of the in vivo activity of the wild-type enzyme
H77N
-
mutant enzyme does not bind the inhibitor ifenprodil
I125A
-
mutant enzyme with 78% of the in vivo activity of the wild-type enzyme
I139A
-
mutant enzyme with 90% of the in vivo activity of the wild-type enzyme
I32A
-
mutant enzyme with 73% of the in vivo activity of the wild-type enzyme
I76A
-
mutant enzyme with 33% of the in vivo activity of the wild-type enzyme
I76L/L78A
-
mutant enzyme with 74% of the in vivo activity of the wild-type enzyme
L129A
-
mutant enzyme with 81% of the in vivo activity of the wild-type enzyme
L133A
-
mutant enzyme with 77% of the in vivo activity of the wild-type enzyme
L135A
-
mutant enzyme with 92% of the in vivo activity of the wild-type enzyme
L196A
-
mutant enzyme with 62% of the in vivo activity of the wild-type enzyme
L198A
-
mutant enzyme with 50% of the in vivo activity of the wild-type enzyme
L204A
-
mutant enzyme with 77% of the in vivo activity of the wild-type enzyme
L33A
-
mutant enzyme with 47% of the in vivo activity of the wild-type enzyme
L35A
-
mutant enzyme with 62% of the in vivo activity of the wild-type enzyme
L43A
-
mutant enzyme with 103% of the in vivo activity of the wild-type enzyme
L49A
-
mutant enzyme with 108% of the in vivo activity of the wild-type enzyme
L50A
-
mutant enzyme with 96% of the in vivo activity of the wild-type enzyme
L65A
-
mutant enzyme with 82% of the in vivo activity of the wild-type enzyme
L67A
-
mutant enzyme with 63% of the in vivo activity of the wild-type enzyme
M122A
-
mutant enzyme with 28% of the in vivo activity of the wild-type enzyme
M193A
-
mutant enzyme with 53% of the in vivo activity of the wild-type enzyme
N194Q
-
mutant enzyme still binds the inhibitor ifenprodil
S134A
-
mutant enzyme with 101% of the in vivo activity of the wild-type enzyme
S38A
-
mutant enzyme with 74% of the in vivo activity of the wild-type enzyme
T124A
-
mutant enzyme with 91% of the in vivo activity of the wild-type enzyme
T126A
-
mutant enzyme with 4% of the in vivo activity of the wild-type enzyme
T126S
-
mutant enzyme still binds the inhibitor ifenprodil
V120A
-
mutant enzyme with 62% of the in vivo activity of the wild-type enzyme
V138A
-
mutant enzyme with 94% of the in vivo activity of the wild-type enzyme
V191A
-
mutant enzyme with 91% of the in vivo activity of the wild-type enzyme
V199A
-
mutant enzyme with 76% of the in vivo activity of the wild-type enzyme
V203A
-
mutant enzyme with 71% of the in vivo activity of the wild-type enzyme
V39A
-
mutant enzyme with 80% of the in vivo activity of the wild-type enzyme
V44A
-
mutant enzyme with 76% of the in vivo activity of the wild-type enzyme
V45A
-
mutant enzyme with 79% of the in vivo activity of the wild-type enzyme
V72A
-
mutant enzyme with 93% of the in vivo activity of the wild-type enzyme
V79A
-
mutant enzyme with 75% of the in vivo activity of the wild-type enzyme
V85A
-
mutant enzyme with 68% of the in vivo activity of the wild-type enzyme
W130A
-
mutant enzyme with 70% of the in vivo activity of the wild-type enzyme
W136A
-
mutant enzyme with 104% of the in vivo activity of the wild-type enzyme
W187A
-
mutant enzyme with 56% of the in vivo activity of the wild-type enzyme
W197A
-
mutant enzyme with 5% of the in vivo activity of the wild-type enzyme
W197F
-
mutant enzyme still binds the inhibitor ifenprodil
W48A
-
mutant enzyme with 87% of the in vivo activity of the wild-type enzyme
W69A
-
mutant enzyme with 17% of the in vivo activity of the wild-type enzyme
W83A
-
mutant enzyme with 97% of the in vivo activity of the wild-type enzyme
Y185A
-
mutant enzyme with 64% of the in vivo activity of the wild-type enzyme
Y189A
-
mutant enzyme with 32% of the in vivo activity of the wild-type enzyme
E116V
-
mutant exhibits 72% of wild type activity
E73V
-
mutant exhibits 100% of wild type activity
H69L
-
mutant exhibits 70% of wild type activity
T119I
-
inactive
D107V
-
inactive
E121V
-
inactive
E78V
-
inactive
H74L
-
inactive
T124I
-
mutant exhibits 10% of wild type activity
W193L
-
inactive
W66L
-
inactive
additional information
-
functional complementation by C-8,7 sterol isomerase of the corresponding sterol mutant in yeast and its characterization by exposure to sigma ligands. The full-length Arabidosis thaliana cDNA encoding C-8,7 sterol isomerase complements the erg2 mutation